Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
250 trials
Recruiting nowPhase 2
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Recruiting nowPhase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Recruiting nowPhase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Recruiting nowPhase 2
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Recruiting nowPhase 2
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Recruiting nowPhase 2
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
Recruiting nowPhase 2
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
Recruiting nowPhase 2
Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer
Recruiting nowPhase 2
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
Recruiting nowPhase 2
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
Recruiting nowPhase 2
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
Recruiting nowPhase 2
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
Recruiting nowPhase 2
Evaluation of XYA02 in Patients With Advanced Solid Tumors
Recruiting nowPhase 2
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
Recruiting nowPhase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation